Discovery UNITY is a multimodality platform that supports multiple types of images and formats.
Compatible formats today (continuously expanding):
Image types supported today (continuously expanding):
Participative research is enabled across the organization and with external experts globally using secure, cloud-based access to data anytime from anywhere, with insights from both certified and validated research modules for analysis.
INCREASED TIME & RISK: pharma pipelines from discovery to launch can take an average of 10-12 years, at an average cost of $2.6B. Significant risk is undertaken as only an average of 1 compound out of 10,000 is introduced to the market.
COMPETITION FOR PATIENT POPULATIONS: Therapies targeting similar pathways limit the market potential and the opportunity to personalize therapy with more well-defined assessment criteria.
R&D pipeline time and costs can be reduced by leveraging Discovery UNITY features:
- clinical research workflows (grading surveys and feedback collection for collaborative and independent data review)
- multimodal data management analysis
- AI models for analysis in wet and dry AMD, Diabetic Retinopathy and Macular Edema, Retinal Vein Occlusion, Geographic Atrophy and Glaucoma.
From a standard analysis workflow of 6 months to 6 weeks reduction of both time and cost of research workflows for a study of >15,000 OCTs
RetinAI Discovery is a CE-marked medical device according to the Medical Devices Regulation (EU) 2017/745
and the AI models are CE-marked devices according to Medical Devices Directive 93/42/EEC
RetinAI Discovery® is a 510(k) FDA Cleared medical device in US.
RetinAI Discovery® and Retinai® are both trademarks of RetinAI Medical AG.
Discovery and AI Models are CE-Marked medical devices since April 2020 & December 2020 respectively.